The American Kidney Fund's ‘A Step Ahead of IgA Nephropathy' Campaign Provides New Resources for Patients Living with IgA Nephropathy
IgA nephropathy is a rare disease that causes inflammation and damage to the kidneys. Over time, this damage reduces the organs' ability to filter waste and fluid from the bloodstream, which can eventually lead to kidney failure. While there is no cure for IgA nephropathy, there are treatments to help treat the disease and slow the damage to the kidneys, potentially delaying or preventing kidney failure.
'We are very pleased to expand our IgA nephropathy campaign with new resources to help patients better understand this rare kidney disease,' said LaVarne A. Burton, AKF President and CEO. 'With support from Novartis, we can provide more information and new tools to help IgAN patients stay 'a step ahead' of their diagnosis and live healthier lives.'
As part of this expansion, AKF has updated the 'A Step Ahead of IgA Nephropathy' campaign webpage. The updates provide more information about proteinuria—protein in the urine. The new resources will also include a downloadable guide about proteinuria progression and an animated explainer video about proteinuria. To further share these resources and raise awareness of IgAN, AKF will also have an Instagram takeover day on June 18 for the campaign.
The 'A Step Ahead of IgA Nephropathy' campaign is part of AKF's ongoing work to increase awareness and understanding of rare kidney diseases and ensure people with rare conditions have access to critical resources. In 2024, AKF launched the Rare Kidney Disease Action Network (RKDAN), a new advocacy network working to ensure the voices of people living with rare kidney diseases are heard and amplified to impact change on the policy level. In its first year, RKDAN focused heavily on issues faced by people living with IgA nephropathy and brought 23 patients to Capitol Hill to advocate for two bills that would significantly improve research, treatment and diagnosis of rare kidney diseases.
###
About the American Kidney Fund
The American Kidney Fund (AKF) fights kidney disease on all fronts as the nonprofit with the greatest direct impact on people with kidney disease. AKF works on behalf of 1 in 7 Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. AKF fights for kidney health for all through programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy. AKF is one of the nation's top-rated nonprofits, investing 97 cents of every donated dollar in programs, and it has received 24 consecutive 4-Star ratings from Charity Navigator as well as the Platinum Seal of Transparency from Candid, formerly known as GuideStar.
For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn.
CONTACT: Nancy Gregory American Kidney Fund (240) 292-7077 ngregory@kidneyfund.org
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
2 hours ago
- USA Today
Ben Askren back in hospital due to infection discovered during first checkup
Less than a week after being discharged, Ben Askren is back in the hospital. Askren, who has been sharing frequent updates on social media after a double lung transplant, revealed that he has returned to the hospital after his first checkup since being released home last Tuesday. Over the past few days, Askren, 40, has shared multiple videos, providing health updates from his home. He has been seen lifting dumbbells and using an exercise bike while sharing inspirational messages. The UFC veteran knows the road ahead is a long one after revealing he died four times while fighting for his life in the hospital, and lost 50 pounds throughout the ordeal. On Monday, Askren shared a video on Instagram, explaining that he had gone in for a checkup and would not be returning home from the hospital immediately due to a chest infection. "Well, as you guys can probably tell, I'm not at home anymore, unfortunately," Askren said in a selfie video while laying in a hospital bed. "I had my first checkup this morning. They didn't like the way the last chest tube looked – thought it was infected. Put me on some antibiotics, and then did a few X-rays, and hopefully we get this solved – fast. "But, right, Stockdale Paradox: It wasn't always going to be smooth. It wasn't always going to be easy. It wasn't going to always be all the way up. So, hopefully this is a small hiccup, and I'm back home getting stronger again. Thought you guys would appreciate the update."
Los Angeles Times
9 hours ago
- Los Angeles Times
Doing it all: Evan Razmjoo excels at speech and debate and finds success in the field of journalism
In comparison to his accomplishments in his high school career, senior Evan Razmjoo said earning the position of editor-in-chief of his school's newspaper didn't seem like something to write home about. 'This is the first time hearing about that,' Razmjoo's brother and rising sophomore at Stanford University, Max Razmjoo, said. 'In the back of my mind, I knew that this was the logical next step for him, and I've got no doubt that he will be the perfect leader for the publication.' Razmjoo has a good amount of leadership experience going into his senior year at Corona del Mar High School. In 2021, Razmjoo co-founded a speech and debate nonprofit alongside his brother, called Youth Prose Scholars. As an experienced debater and public speaker himself, Razmjoo said he wanted to start YPS to spread speech and debate education to underfunded schools that didn't have the budget for debate teams. Now mentoring and sponsoring more than 27 debate teams, YPS has grown beyond Orange County and has allowed Razmjoo to spread public speaking education worldwide. 'Through [YPS] I've been able to have a lot of meaningful interactions with various kids we've taught, from California to Japan,' Razmjoo said. 'We've helped students use their voices for meaningful change, and have taught them how to advocate for themselves. I hope we can continue to expand into the far future.' HSI isn't new to Razmjoo either– he's been a member of the Student Advisory Board since fall 2024 and is a frequent contributor to the site. Razmjoo said he saw the HSI internship as an opportunity to broaden his skills in journalistic writing and make connections. He said the story he pitched on his application came to him while 'just going through random studies.' Ironically, it was during this scrolling that he stumbled upon a study from the National Institute of Health, highlighting the detrimental effects of doomscrolling on the brain. 'I saw some alarming statistics on the significant effects of social media on our brain, and it caught my eye because it mentioned doomscrolling, which is such a Gen-Z thing,' Razmjoo said. While there are many negative effects of social media usage, Razmjoo said he's also interested in using it as 'a tool' for young journalists to promote their work to a wider audience. One of his main goals for next year is to use his role as EIC to boost engagement and readership for his school paper, the CDM Trident. 'Engagement wasn't really a topic we discussed at school, but I always thought it was kind of a big deal. That inspired me to plan various activities, such as doing scavenger hunts for newspapers and fun surveys on our Instagram,' Razmjoo said. 'I've been working with our social media team, and I'm hoping that our advertising and subscriptions will double next year.' Despite being so involved with journalism today, Max Razmjoo says he 'never would have pictured' his brother as a journalist five years ago, but is certain that the work they've done together for YPS has laid the foundation for a successful future in the field. He notes that his brother winning the New York Times' Teen Tiny Memoirs competition solidified this certainty, as his brother's winning piece demonstrated 'his ability to tell stories in impactful ways.' 'In his story, he connected his experiences playing basketball to my dad's immigration to the U.S. from Iran, creating this powerful metaphor,' Max Razmjoo said. 'I really admire how he always steps outside of his comfort zone to push his own creativity.' During his time at the HSI internship, Evan Razmjoo hopes to learn more about multimedia journalism and expand his knowledge of professional tactics to bring back to his own writing and school paper. 'With a newspaper like the L.A. Times, there's always a lot to learn from the amazing professional journalists on staff,' Razmjoo said. 'I think it's essential for people to have quality information, because that leads to positive discourse. I want to learn how to make my work meaningfully inform my community in that same way.' Related
Yahoo
10 hours ago
- Yahoo
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
The second-quarter 2025 reporting cycle for the Medical sector is about to pick up pace this week, as most firms are slated to share their earnings results over the next two weeks. The sector mainly comprises pharma/biotech and medical device companies. The earnings season for the drug and biotech sector kicked off around mid-July when bellwether Johnson & Johnson reported strong second-quarter results, beating estimates for earnings and sales. J&J consequently raised its total revenue expectation as well as its adjusted earnings expectation for the year. Among other pharma bigwigs, Novartis beat second-quarter earnings and revenue estimates, driven by a year-over-year increase in sales of key drugs. Based on strong momentum, Novartis raised its annual guidance for core operating income. Roche also posted solid growth in the first half of 2025 as high demand for key drugs like Phesgo (breast cancer), Xolair (food allergies), Hemlibra (hemophilia A), Vabysmo (severe eye diseases) and Ocrevus (multiple sclerosis) offset the decline in sales of legacy drugs. Per the Earnings Trends report, as of July 23, 15% of the companies in the Medical sector — representing 27.2% of the sector's market capitalization — reported quarterly earnings. Of these, 88.9% outperformed earnings estimates, while 100% beat the same for revenues. Earnings increased 0.4% year over year, while revenues increased 10.2%. Overall, second-quarter earnings of the Medical sector are expected to increase 0.9%, while sales are expected to rise 7.9% from the year-ago quarter. Merck MRK, AstraZeneca AZN, Bristol Myers BMY, AbbVie ABBV and Moderna MRNA are all slated to release theirquarterly results this week. Let us see how these biotech/pharma companies are likely to have performed in the soon-to-be-reported quarter. Merck Merck has an encouraging earnings track record. It beat earnings estimates in each of the last four quarters, delivering an average earnings surprise of 3.82%. In the last reported quarter, MRK beat earnings estimates by 3.26%. Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Merck has an Earnings ESP of -0.18% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for MRK's earnings is pegged at $2.01 per share. You can see the complete list of today's Zacks #1 Rank stocks here. Merck's top-line growth in the second quarter is likely to have been driven by higher sales of its blockbuster cancer drug Keytruda, attributable to additional indications and patient demand. Merck is scheduled to release its quarterly earnings results before the opening bell on July 29. Merck & Co., Inc. Price and Consensus Merck & Co., Inc. price-consensus-chart | Merck & Co., Inc. Quote AstraZeneca AstraZeneca has a mixed earnings track recordover the trailing four quarters. The company's earnings beat estimates in three of the last four quarters, missing the mark on one occasion. On average, AZN registered an earnings surprise of 4.24% in the last four quarters. In the last reported quarter, AstraZeneca beat earnings estimates by 12.73%. AstraZeneca has an Earnings ESP of -0.64% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for AZN's earnings is pegged at $1.09 per share. Sales of AstraZeneca's key medicines, mainly cancer drugs — Lynparza, Tagrisso and Imfinzi — and diabetes medicine Farxiga, are expected to have driven the company's top line in the second quarter, backed by strong demand trends. AstraZeneca is scheduled to release its quarterly earnings results before the opening bell on July 29. AstraZeneca PLC Price and Consensus AstraZeneca PLC price-consensus-chart | AstraZeneca PLC Quote Bristol Myers Bristol Myers has an excellent earnings track record. BMY's earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 20.16%. In the last reported quarter, Bristol Myers' earnings surpassed estimates by 19.21%. Bristol Myers has an Earnings ESP of -7.92% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for BMY's earnings is pegged at $1.18 per share. Bristol Myers' revenues in the second quarter of 2025 are likely to have been impacted by a decline in sales from its legacy drugs, which include Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane, among others. However, the expected decline is likely to have been partially offset by an increase in the sales of BMY's growth products like Opdivo, Yervoy, Reblozyl, Breyanzi, Zeposia, Opdualag and others. Bristol Myers is slated to release its quarterly earnings results before the opening bell on July 31. Bristol Myers Squibb Company Price and Consensus Bristol Myers Squibb Company price-consensus-chart | Bristol Myers Squibb Company Quote AbbVie AbbVie has an impeccable earnings track record to date. ABBV's earnings beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 2.55%. In the last reported quarter, AbbVie's earnings beat estimates by 2.93%. AbbVie has an Earnings ESP of 0.00% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for ABBV's earnings is pegged at $2.89 per share. AbbVie's top line is expected to have been driven by robust sales of key drugs Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant contributions from newer drugs, namely Ubrelvy, Elahere, Epkinly and Qulipta. ABBV is scheduled to report its quarterly earnings results on July 31, before the opening bell. AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote Moderna Moderna has an excellent earnings track record. It beat earnings estimates in each of the last four quarters, delivering an average earnings surprise of 31.60%. In the last reported quarter, MRNA beat earnings estimates by 13.70%. Moderna has an Earnings ESP of +7.22% and a Zacks Rank #3 at present, indicating a positive surprise this time around. The Zacks Consensus Estimate for MRNA's loss per share is pegged at $2.99. Moderna's second-quarter revenues are expected to have been driven by sales of its COVID-19 vaccine, Spikevax. However, with declining demand for COVID-related products, investors are advised to focus more on updates regarding the company's broader pipeline. Moderna is slated to release its quarterly earnings results before the opening bell on Aug. 1. Moderna, Inc. Price and Consensus Moderna, Inc. price-consensus-chart | Moderna, Inc. Quote Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Moderna, Inc. (MRNA) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
